Yasuhiro Hagiwara

J-GLOBAL         Last updated: Apr 9, 2019 at 12:05
 
Avatar
Name
Yasuhiro Hagiwara
Affiliation
The University of Tokyo
Research funding number
60844040
ORCID ID
0000-0003-3792-5368

Research Areas

 
 

Academic & Professional Experience

 
Apr 2019
 - 
Today
Assistant Professor, Department of Biostatistics, Division of Health Sciences and Nursing, Graduate School of Medicine, The University of Tokyo
 

Education

 
Apr 2016
 - 
Mar 2019
Division of Health Sciences and Nursing, Graduate School of Medicine, The University of Tokyo
 
Apr 2014
 - 
Mar 2016
School of Public Health, Graduate School of Medicine, The University of Tokyo
 
Apr 2012
 - 
Mar 2014
School of Integrated Health Sciences, Faculty of Medicine, The University of Tokyo
 
Apr 2010
 - 
Mar 2012
College of Arts and Sciences, The University of Tokyo
 

Awards & Honors

 
Sep 2018
Best Student Poster Research Presentation, ISPOR Asia Pacific 2018
 

Published Papers

 
REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients
Shitara K, Yamanaka T, Denda T, Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Yoshino T.
Annals of Oncology   30(2) 259-265   Feb 2019   [Refereed]
Ishimaru M, Matsui H, Ono S, Hagiwara Y, Morita K, Yasunaga H
The British journal of surgery   105(12) 1688-1696   Aug 2018   [Refereed]
Hagiwara Y, Fukuda M, Matsuyama Y
American journal of epidemiology   187(11) 2481-2490   Jul 2018   [Refereed]
Hagiwara Y, Ohashi Y, Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, JASPAC 01 Study Group.
European journal of cancer (Oxford, England : 1990)   93 79-88   Apr 2018   [Refereed]
Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Kaneko S, Nakashima O, Kadoya M, Izumi N, Takayama T, Ku Y, Kumada T, Kubo S, Kokudo T, Hagiwara Y, Kokudo N, Liver Cancer Study Group of Japan.
Liver international : official journal of the International Association for the Study of the Liver   38(3) 484-493   Mar 2018   [Refereed]
Hagiwara Y, Shiroiwa T, Shimozuma K, Kawahara T, Uemura Y, Watanabe T, Taira N, Fukuda T, Ohashi Y, Mukai H
PharmacoEconomics   36(2) 215-223   Feb 2018   [Refereed]
Kawahara T, Shimozuma K, Shiroiwa T, Hagiwara Y, Uemura Y, Watanabe T, Taira N, Fukuda T, Ohashi Y, Mukai H
Oncology   94(2) 107-115   2018   [Refereed]
Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Kawahara T, Ohsumi S, Hozumi Y, Sagara Y, Ohashi Y, Mukai H
BMC cancer   17(1) 773   Nov 2017   [Refereed]
Shinozaki T, Hagiwara Y, Matsuyama Y
Epidemiology (Cambridge, Mass.)   28(4) e40-e41   Jul 2017   [Refereed]
Yamaue H, Shimizu A, Hagiwara Y, Sho M, Yanagimoto H, Nakamori S, Ueno H, Ishii H, Kitano M, Sugimori K, Maguchi H, Ohkawa S, Imaoka H, Hashimoto D, Ueda K, Nebiki H, Nagakawa T, Isayama H, Yokota I, Ohashi Y, Shirasaka T
Cancer chemotherapy and pharmacology   79(4) 813-823   Apr 2017   [Refereed]
Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Doihara H, Akabane H, Kashiwaba M, Watanabe T, Ohashi Y, Mukai H.
Quality of LIfe Reserch   26(2) 445-453   Feb 2017   [Refereed]
Hagiwara Y, Ohashi Y, Okusaka T, Ueno H, Ioka T, Boku N, Egawa S, Hatori T, Furuse J, Mizumoto K, Ohkawa S, Yamaguchi T, Yamao K, Funakoshi A, Cheng AL, Kihara K, Sato A, Tanaka M
ESMO open   2(1) e000151   2017   [Refereed]
Mukai H, Hagiwara Y, Imi K, Isaka H, Watanabe K, Matsuyama Y, SELECT BC Study Group.
Oncology   93(5) 315-322   2017   [Refereed]

Conference Activities & Talks

 
Patient-reported outcomes with trastuzumab monotherapy versus trastuzumab plus standard chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients (RESPECT): A randomized, open-label, phase 3 clinical trial
Kobayashi K, Taira N, Sawaki M, Sagawa N, Baba S, Saito T, Kawahara T, Hagiwara Y, Uemura Y, Shimozuma K, Ohashi Y, Mukai H
San Antonio Breast Cancer Symposium 2018   Dec 2018   
Analysis of cognitive function in elderly HER2-positive breast cancer patients receiving either trastuzumab monotherapy or trastuzumab plus chemotherapy as a postoperative adjuvant treatment: A cognitive function sub-study of a randomized, open-label, pha
Takahashi M, Sawaki M, Hagiwara Y, Uemura Y, Kawahara T, Shimozuma K, Ohashi Y, Saito T, Baba S, Kobayashi K, Mukai H, Taira N
San Antonio Breast Cancer Symposium 2018   Dec 2018   
The EQ-5D index of elderly patients with HER-2 positive breast cancer: results from the randomized N-SAS BC 07 trial for adjuvant trastuzumab with and without chemotherapy
Hagiwara Y, Taira N, Saito T, Baba S, Kobayashi K, Kawahara T, Shiroiwa T, Fukuda T, Shimozuma K, Uemura Y, Mukai H, Ohashi Y, Sawaki M
International Society for Pharmacoeconomics and Outcome Research Asia Pacific 2018 Conference   Sep 2018   
REVERCE: randomized phase II study of regorafenib followed by cetuximab vs. reverse sequence for colorectal cancer
山内理海,設楽紘平,山中竹春,傳田忠道,辻靖,小松嘉人,小林良充,古瀬 純司,加藤健志,沖英次,安藤高志,萩原康博,大橋靖雄,吉野孝之
第16回日本臨床腫瘍学会学術集会   Jul 2018   
G-estimation of structural nested restricted mean time lost models to estimate effect of time-varying treatment on survival outcome
Hagiwara Y, Shinozaki T, Matsuyama Y
29th International Biometric Conference   Jul 2018   
REVERCE: randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: quality of life analysis
Yoshino T, Yamanaka T, Denda T,Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Shitara K
European Society for Medical Oncology World Congress on Gastrointestinal Cancer 2018   Jun 2018   
REVERCE: randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated With fluoropyrimidine, oxaliplatin, and irinotecan— biomarker analysis
Tsuji Y, Shitara K, Yamanaka T, Denda T, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Yoshino T
American Society of Clinical Oncology Annual Meeting 2018   Jun 2018   
QOLの統計的評価:最近の成果から [Invited]
萩原康博,大橋靖雄
第89回QOL研究会   17 Sep 2017   
SELECT BC のQOL、医療経済評価およびEQ-5Dについて: EQ-5Dへの有害事象の影響 [Invited]
萩原康博
第11回CSP-HOR年会   1 Jul 2017   
Impacts of adverse events on health-related quality of life in patients receiving first-line chemotherapy for metastatic breast cancer : results from randomized phase III SELECT BC study.
Hagiwara Y, Shimozuma K, Shiroiwa T, Kawahara T, Uemura Y, Watanabe T, Taira N, Fukuda T, Ohashi Y, Mukai H.
International Society for Pharmacoeconomics and Outcome Research 19th Annual European Congress   2 Nov 2016   
Cost-effectiveness of first-line S-1 therapy for metastatic breast cancer patients compared with taxanes: an analysis based on the randomized phase III SELECT BC trial.
Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Kawahara T, Ohsumi S, Hozumi Y, Sagara Y, Ohashi Y, Mukai H.
International Society for Pharmacoeconomics and Outcome Research 19th Annual European Congress   2 Nov 2016   
Responder analyses of patient-reported outcomes for evaluating the clinical significance of first-line S-1 over taxane therapy among patients with metastatic breast cancer: the open-label randomized phase III SELECT BC trial.
Kawahara T, Shimozuma K, Shiroiwa T, Hagiwara Y, Uemura Y, Watanabe T, Fukuda T, Ohashi Y, Mukai H.
International Society for Quality of Life Research 23rd Annual Conference   21 Oct 2016   
Multicenter randomized phase II study comparing alternate-day oral therapy using S-1 with the standard regimen as a first-line treatment for patients with locally advanced and metastatic pancreatic cancer: PAN-01 study.
Sho M, Shimizu A, Yanagimoto H, Nakamori S, Okusaka T, Ishii H, Kitano M, Sugimori K, Maguchi H, Ohkawa S, Imaoka H, Hashimoto D, Ueda K, Nebiki H, Nagakawa T, Isayama H, Hagiwara Y, Ohashi Y, Shirasaka T, Yamaue H.
American Society for Clinical Oncology annual meeting 2016   Jun 2016   
Estimation of modified effectiveness in randomized trials with subsequent treatments using dynamic marginal structural models
Hagiwara Y, Shinozaki T, Matsuyama Y
UK Causal Inference Meeting 4th annual meeting   12 Apr 2016   
Long-term EQ-5D score for patients with metastatic breast cancer; comparison of first-line oral S-1 and Taxane therapies in the randomized SLECT trial
Fukuda T, Shiroiwa T, Simozuma K, Mori M, Doihara H, Akabane H, Kashiwaba M, Watanabe T, Hagiwara Y, Ohashi Y, Mukai H
International Society for Pharmacoeconomics and Outcome Research 18th Annual European Congress   9 Nov 2015   
Estimation of modified effectiveness in confirmatory cancer clinical trials using dynamic marginal structural models
Hagiwara Y
PeSeTo International Symposium on Public Health 2016   15 May 2015